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Background: Lung cancer is mainly diagnosed at advanced or locally advanced stages, usually when 
symptoms become evident. However, sometimes it may be diagnosed incidentally during routine care, while 
patients are still asymptomatic. Prognosis differences based on symptomatic presentation have been partially 
explored. Our aim was to analyze the prognostic value of the initial symptomatic state of the patients in a 
general lung cancer cohort.
Methods: Observational ambispective study including patients consecutively diagnosed with primary 
lung cancer between January 2016 and December 2018 via the lung cancer Fast Diagnostic Track (FDT). 
Patients were followed up until death or the end of the study in September 2019. Asymptomatic patients 
were compared with patients presenting symptoms. Overall survival (OS) of both groups was compared using 
the log-rank test. Cox regression analysis was performed to clarify the effect of the symptomatic status at 
diagnosis on survival. Additionally, propensity score (PS) matching analysis was performed.
Results: A total of 267 patients were analyzed; 83.5% were men, with a mean (SD) age at diagnosis of 
68 (10.7) years. Incidental diagnosis was ascertained in 24.7% of cases. Asymptomatic patients presented 
more frequently stage I and II disease compared to symptomatic patients (51.5% vs. 14%), and exhibited a 
significantly better prognosis, with a 3-year OS of 63.6% (vs. 30.3%) and a median OS that was not reached 
during follow-up (vs. 10.3 months). With an adjusted multivariate Cox proportional hazard model, we 
obtained a HR (95% CI) of 2.63 (95% CI, 1.6–4.2; P<0.0001) associated with symptomatic presentation 
independently of age, sex, stage at diagnosis and ECOG scale. In addition, after performing the propensity 
score matching analysis, the Cox regression model continued to show a significantly worse prognosis for 
patients presenting with symptoms (P=0.041).
Conclusions: Lung cancer patients who are asymptomatic at diagnosis exhibit a significantly better 
prognosis, regardless of the stage of the disease, underlining the importance of an early diagnosis.
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Introduction
Lung cancer is the most common cause of mortality related 
to cancer worldwide and represents a major health problem 
(1). The stage of the disease is one of the main prognostic 
factors and implies significant differences in terms of 
survival (2). Unfortunately, approximately 60% of patients 
are diagnosed with locally advanced or advanced stage 
disease, exhibiting five-year survival rates that range from 
12% to 41% and are lower than 10%, respectively (2,3). 
Many factors may contribute to this late diagnosis (4,5). 
The paucisymptomatic nature of lung cancer, especially at 
its initial phases, could be one of them. Early lung cancer 
is almost always asymptomatic, and it takes it several years 
to grow and produce signs or symptoms that may alert the 
patient (6,7). When this occurs, most tumors may be at 
locally advanced or advanced stages, and the prognosis will 
be much poorer.
The potential prognostic significance of symptoms at 
the time of diagnosis of lung cancer has been explored in 
previous studies, suggesting that lung cancer patients who 
are asymptomatic may have a better prognosis in terms of 
overall survival (OS) than those who present with symptoms 
(8-13). However, studies specifically designed to analyze 
differences among these groups are limited (8,9,13), and 
some are restricted to specific lung cancer cohorts, such 
as non-small cell lung cancer (NSCLC) patients (13) or 
surgically treated patients (9,11,12). Additionally, these 
studies have been carried out on the basis databases from 
registers, surveys or hospital records, but do not specify 
the clinical care model from which these data have been 
collected.
Our work has been carried out and coordinated from the 
lung cancer Fast Diagnostic Track (FDT), the optimal care 
pathway where all patients from our region with suspicion 
of lung cancer are centralized to perform the diagnosis 
process. This consists of a structured care plan that aims to 
provide a management according to the up-to-date evidence 
with a special focus on tasks, its timing and sequence, to 
ensure a timely care for lung cancer patients (14). Moreover, 
this pathway positions us in front of a general lung cancer 
population from a geographic area, allowing us to perform 
studies with a “real-life” perspective of healthcare.
Taking this into account, our aim was to perform a 
population study including all patients diagnosed with lung 
cancer from a circumscribed area, to reflect the potential 
prognostic value of clinical presentation at diagnosis.
We present the following article in accordance with the 




Observational ambispective study performed at the Lung 
Cancer FDT of the Respiratory Department of the 
University Hospital Arnau de Vilanova from Lleida, the 
reference tertiary hospital of our region.
The lung cancer FDT
We offer coverage to the geographic area of Lleida, which 
includes approximately 450,000 people and is mainly 
characterized by its dispersed population. Because of these 
demographic characteristics, our Respiratory Department 
launched the lung cancer FDT, a monographic consultation 
where all patients with suspicion of lung cancer are submitted. 
This consultation performs the initial diagnostic management 
of patients operating as an optimal care pathway. The 
professional team includes both a nurse manager and a 
pulmonologist specially dedicated to the diagnosis of lung 
cancer who coordinate the diagnostic process of patients. 
Criterion for referral is the presence of any image suspected 
of malignancy in both simple chest radiography or computed 
tomography. When the imaging modality by which patient 
is referred is chest X-ray, the FDT consultation requests and 
completes the study with a CT scan. Patients can be referred 
from primary care, specialized care or emergency. New 
cases are submitted online and reviewed by the physician in 
charge. If the case is considered suspected of lung cancer, it is 
accepted to enter the FDT, and the nurse manager provides 
the patient the first face-to-face appointment. If the case is not 
considered suspicious of neoplasia, the submission is rejected 
and a message is sent telematically to the doctor requesting 
the visit explaining the decision.
At the first visit, information about medical history, 
anamnesis and physical examination, is collected, and 
available imaging tests are reviewed. The pulmonologist 
draws up the diagnostic plan, requesting all subsequent 
diagnostic tests (radiological extension study, mediastinal 
staging study, techniques for pathological diagnosis and 
pulmonary function tests). The FDT has a particular 
priority in the programming of these tests and time slots 
specifically dedicated in the different departments. The 
diagnostic plan is provided in writing to the patient and 
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the nurse manager schedules all the tests. At the nurse 
manager’s office, anti-smoking health education and a brief 
psychological assessment to evaluate the need to refer for 
psychological support, are also carried out.
When all requested tests have been performed, the case 
is scheduled in the Thoracic Oncology MDT meeting 
agenda. Departments included in the MDT are Respiratory 
Medicine, Thoracic Surgery, Medical Oncology, Radiation 
Oncology, Radiology, Pathology, as well as counting with 
the nurse manager. The team meets on a weekly basis, 
assessing both cases of newly diagnosed patients for which 
treatment needs to be established, as well as cases of already 
treated patients where diagnostic or therapeutic doubts arise 
during follow-up. After the MDT evaluation, the FDT 
final visit takes place, where the results and the therapeutic 
strategy to be followed are reported and the patient is 
submitted to the subsequent treating physicians.
Study population
We included all patients assessed at the Lung Cancer FDT 
and diagnosed with primary lung cancer, both NSCLC 
and small cell lung cancer (SCLC), from January 2016 
to December 2018. Exclusion criteria included patients 
diagnosed with thoracic malignancies other than primary 
lung cancer, patients without pathologic confirmation of 
malignancy of the suspicious lesion and patients with loss 
of follow-up in which survival could not be confirmed. 
Patients were followed up until death or until the end of the 
study in September 2019.
Definitions
Lung cancer was diagnosed when both a radiological image 
and pathological confirmation of malignancy coexisted. 
Incidental diagnosis was defined as a radiological finding of 
lung cancer on any chest image from patients without any 
previous lung cancer symptoms, or from chronic respiratory 
patients with daily respiratory symptoms, without 
any significant symptomatic changes that would have 
necessitated a medical consultation or an imaging request. 
If a routine chest image was performed in these patients and 
they reported no change in their symptoms, lung cancer was 
considered incidental.
Development of field work and collected data
The FDT nurse manager performed a prospective daily 
registry of patients evaluated at the consultation, where 
basic data were collected: age, sex, date of first appointment 
and dates of performance and results from complementary 
tests. Further data regarding medical history and anamnesis 
were collected prospectively by the physician on first visit. 
This physician thoroughly explored the symptomatic 
development of the disease, identifying the most likely 
first symptom of it. During the diagnostic process, data 
about pulmonary function, pathological results, stage of 
the disease and first treatment performed, were collected. 
Survival status was checked retrospectively by the physician 
using hospital and primary care electronic databases.
Clinical variables included age, sex, smoking history, 
comorbidities and symptom of presentation. Smoking 
history was categorized as absence (never smokers were 
defined as having smoked less than 100 cigarettes in their 
lifetime) (15) or presence of the habit (including both 
current smokers and former smokers). The quantitative 
assessment of tobacco exposure was expressed as pack-years. 
Comorbidities were identified and assessed according to 
the age-adjusted Charlson comorbidity index (ACCI) (16). 
It was calculated for each patient based on 19 diagnoses 
obtained from the review of the patient’s medical history 
and adjusted for age.
The lung cancer symptom that led to initiation of 
the diagnostic process was defined as the symptom of 
presentation. Established categories were based on 
most frequent symptomatology referred at consultation. 
Symptoms could be respiratory, including cough, 
dyspnea,  hemoptys is ,  chest  pain and respiratory 
infection/exacerbation; and non-respiratory, including 
musculoskeletal pain, dysphagia, neurological deficit, 
constitutional syndrome and others less frequent. When 
there were no symptoms, the case was considered an 
incidental diagnosis, as defined above.
Pulmonary function tests (spirometry and lung volume 
and diffusion capacity assessments) were collected from all 
patients, except in patients who were not able to perform 
the maneuvers. All tests were performed by specialized 
respiratory nurses. The Masterscreen™ PFT (Jaeger™), 
an all-in-one device capable of performing spirometry 
and measuring the diffusion capacity of carbon monoxide 
(DLCO), was used. The acceptability and reproducibility 
criteria followed the Spanish Society of Pulmonology and 
Thoracic Surgery (SEPAR) and the European Respiratory 
Society (ERS) guidelines (17,18). A bronchodilator test 
was performed on all patients by administering 400 μg of 
salbutamol in 4 puffs (100 μg per puff) in 30-s intervals. The 
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DLCO was determined by the single-breath technique (19). 
Collected values included the ratio of the forced expiratory 
volume in one second to forced vital capacity (FEV1/FVC), 
FEV1, and DLCO.
Lung cancer stage at the time of diagnosis was 
categorized according to the tumor, node, metastasis 
staging system corresponding to the most recent edition 
(8th edition) (2). Stages were defined as early-stage or 
localized for stage I and II; locally advanced for stage 
III and advanced for stage IV. Information about lung 
cancer histology was collected; for patients with NSCLC, 
the histologic subtype was recorded. The performance 
status of patients was assessed by the Eastern Cooperative 
Oncology Group (ECOG) scale. First treatment modality 
was also recorded, and included surgical treatment, systemic 
oncological treatment, radiotherapy, chemoradiotherapy 
and best supportive care.
At the time of data review, survival status was verified. 
The date of death was determined from the hospital 
electronic and primary care databases.
The study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013). The study was 
approved by the ethics committee of the centre (Clinical 
Research Ethics Committee of the Arnau de Vilanova-
Santa Maria Hospital University Hospital) (No. 1951) and 
was exempted from obtaining written informed consent 
from patients because of being based on anonymised 
data routinely collected in standard clinical practice, not 
affecting clinical care of patients, and the retrospective 
component of its design.
Statistical analysis
Descriptive statistics including the mean (SD) or median 
(IQR) were estimated for quantitative variables with a 
normal or nonnormal distribution, respectively, while 
absolute and relative frequencies were used for qualitative 
variables. Normality of the distribution was analyzed using 
the Shapiro-Wilks test. Participant characteristics were 
compared using Student’s t-test or the nonparametric 
Mann-Whitney U and Kruskal-Wallis tests for skewed 
data. OS was defined as the time in months between the 
diagnosis of lung cancer and all-cause death and estimated 
using the Kaplan-Meier method. To compare the survival 
curves, the log-rank test was used. Multivariate analysis was 
performed using a Cox proportional hazards regression 
model. Additionally, propensity score (PS) matching 
analysis was performed using logistic regression model 
including age, sex, ECOG and disease stage as confounders. 
One-to-one PS matching without replacement was done to 
match asymptomatic to symptomatic patients and matched 
pairs were used in a supplemental analysis.
All tests were two-sided, and P values <0.05 were 
considered statistically significant. R statistical software, 
version 3.5.1 (R Project for Statistical Computing) was used 
for all analyses.
Results
We recruited 269 patients diagnosed with primary lung 
cancer through our Lung Cancer FDT consultation of 
which 267 were analyzed (Figure 1). The mean (SD) age 
was 68 (10.7) years at diagnosis, 86.4% of patients had a 
smoking history with a median [p25th;p75th] of 50 [30;68.5] 
pack-years. In 24.7% of patients the diagnosis of lung 
cancer was incidental. The OS was 11.9 months, and 61.4% 
of the patients died during the follow-up period.
Asymptomatic patients were significantly older, more 
frequently diagnosed with I and II stage disease and more 
frequently underwent surgical treatment as the initial 
approach. With respect to comorbidities, no differences 
were observed on the global ACCI score but, asymptomatic 
patients showed a higher prevalence of COPD (P=0.018) 
and cerebrovascular disease (P=0.020) (Table 1). Regarding 
clinical presentations in the symptomatic group, most 
patients presented respiratory symptoms (66.1%). When 
it comes to stage, patients with localized stages I and II 
presented more frequently with exacerbation/respiratory 
infection, while patients with locally advanced and advanced 
stages III and IV showed a greater variety of symptoms 









  1 missing diagnosis date
  1 moved of address
Figure 1 Flowchart of the study recruitment.
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Table 1 Clinical and demographic characteristics of the patients.
Characteristic All, n=267 Asymptomatic, n=66 Symptomatic, n=201 P value n
Age, mean (SD), years 68.0 (10.7) 70.9 (9.92) 67.0 (10.8) 0.008 267
Sex, male, n (%) 223 (83.5%) 55 (83.3%) 168 (83.6%) 1.000 267
Stage, n (%): <0.001 266
I 46 (17.3%) 25 (37.9%) 21 (10.5%)
II 16 (6.02%) 9 (13.6%) 7 (3.50%)
III 78 (29.3%) 18 (27.3%) 60 (30.0%)
IV 126 (47.4%) 14 (21.2%) 112 (56.0%)
Smoking status, yes, n (%) 133(86.4%) 29 (85.3%) 104 (86.7%) 0.783 154
Total tobacco exposure, median [p25th;p75th] 50.0 [30.0;68.5] 50.0 [31.2;60.0] 50.0 [30.0;74.2] 0.450 242
FEV1/FVC, <70, n (%) 115 (54.0%) 31 (49.2%) 84 (56.0%) 0.449 213
FEV1 %, mean (SD) 74.5 (21.4) 77.4 (22.7) 73.3 (20.9) 0.231 213
DLCO, mean (SD), mL CO/min/mmHg 67.6 (18.0) 67.2 (19.6) 67.7 (17.3) 0.867 199
Histology, n (%) 0.716 267
Squamous 91 (34.1%) 24 (36.4%) 67 (33.3%)
Adenocarcinoma 110 (41.2%) 29 (43.9%) 81 (40.3%)
Small cell lung cancer 37 (13.9%) 8 (12.1%) 29 (14.4%)
Other* 29 (10.9%) 5 (7.58%) 24 (11.9%)
Deaths, n (%) 164 (61.4%) 24 (36.4%) 140 (69.7%) <0.001 267
Initial treatment, n (%) <0.001 264
Surgery 56 (21.2%) 28 (42.4%) 28 (14.1%)
Chemotherapy 117 (44.3%) 20 (30.3%) 97 (49.0%)
Chemoradiotherapy 57 (21.6%) 8 (12.1%) 49 (24.7%)
Radiotherapy 17 (6.44%) 7 (10.6%) 10 (5.05%)
Best supportive care 17 (6.44%) 3 (4.55%) 14 (7.07%)
ECOG scale, n (%) 0.885 254
0–1 220 (86.6%) 52 (85.2%) 168 (87.0%)
>1 34 (13.4%) 9 (14.8%) 25 (13.0%)
ACCI score, median [p25th;p75th] 7.00 [5.00;9.00] 7.00 [5.00;8.75] 7.00 [5.00;9.00] 0.087 267
Myocardial infarction, n (%) 28 (10.5%) 10 (15.2%) 18 (8.96%) 0.232 267
Congestive heart failure, n (%) 10 (3.75%) 2 (3.03%) 8 (3.98%) 1.000 267
Peripheral vascular disease, n (%) 30 (11.2%) 8 (12.1%) 22 (10.9%) 0.970 267
Cerebral vascular disease, n (%) 18 (6.74%) 9 (13.6%) 9 (4.48%) 0.020 267
Dementia, n (%) 7 (2.62%) 2 (3.03%) 5 (2.49%) 0.684 267
Chronic obstructive pulmonary disease, n (%) 122 (45.7%) 39 (59.1%) 83 (41.3%) 0.018 267
Diabetes, n (%) 78 (29.2%) 23 (34.8%) 55 (27.4%) 0.315 267
Diabetes with end-organ damage, n (%) 11 (4.12%) 3 (4.55%) 8 (3.98%) 0.736 267
Moderate/severe renal disease, n (%) 16 (5.99%) 3 (4.55%) 13 (6.47%) 0.768 267
Moderate/severe liver disease, n (%) 11 (4.12%) 2 (3.03%) 9 (4.48%) 1.000 267
*, other histologies: large cell neuroendocrine carcinoma, carcinoid tumors (typical and atypical), adenosquamous carcinoma and 
undifferentiated non-small cell lung cancer-not otherwise specified (NOS). Total tobacco exposure is expressed in pack-years. SD, 
standard deviation; [p25th;p75th], 25 and 75 percentiles; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. DLCO, 
the diffusion capacity of carbon monoxide; ECOG, Eastern Cooperative Oncology Group. ACCI, age-adjusted Charlson comorbidity index.
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including nonrespiratory, although the most frequent 
presentation was cough (Table 2).In terms of prognosis, at 
the end of the follow-up period, survival was significantly 
superior in the asymptomatic group, with a 3-year OS of 
63.6% versus 30.3% in symptomatic patients (P<0.001). 
Accordingly, the median OS of asymptomatic patients was 
not achieved during the 36 months of follow-up, while in 
the symptomatic group, the median OS was 10.3 months 
(P<0.001) (Figure 2).
Multivariate Cox regression analysis was performed to 
clarify the effect of symptomatic status at the time of the 
initial diagnosis on survival. After adjusting the model for 
age, sex, disease stage and ECOG scale we obtained an HR 
of 2.63 (95% CI, 1.6–4.2; P<0.0001) for symptomatic versus 
asymptomatic patients, meaning that the risk of death was 
2.63 times higher in symptomatic than in asymptomatic 
patients at any particular point in time (Figure 3).
As a secondary analysis, propensity score matching 
analysis was done to reduce the effect of potential 
confounding factors. No statistically significant differences 
were found between asymptomatic and symptomatic 
matched pairs (Table S1). Cox regression analysis using 
propensity matched patient pairs showed statistically 
significant worse prognosis for symptomatic patients 
(P=0.041), similar to results observed in the main analysis 
(Figure S1).
Differences within symptomatic patients between those 
presenting respiratory and non-respiratory symptoms, were 
also explored. Both groups presented mostly advanced and 
locally advanced stages at diagnosis, and no statistically 
significant differences were observed on survival (Table S2, 
Table 2 Leading symptoms in symptomatic patients categorized by stage
Symptoms ALL, N=200** I, N=21 II, N=7 III, N=60 IV, N=112
Respiratory symptoms, n (%)
Cough 40 (20.0) 0 (0.00) 2 (28.6) 19 (31.7) 19 (17.0)
Dyspnea 20 (10.0) 0 (0.00) 0 (0.00) 7 (11.7) 13 (11.6)
Hemoptysis 23 (11.5) 3 (14.3) 2 (28.6) 5 (8.33) 13 (11.6)
Chest pain 20 (10.0) 1 (4.76) 1 (14.3) 8 (13.3) 10 (8.93)
Exacerbation/respiratory infection 30 (15.0) 10 (47.6) 2 (28.6) 10 (16.7) 8 (7.14)
Non-respiratory symptoms, n (%)
Musculoskeletal pain 23 (11.5) 4 (19.0) 0 (0.00) 2 (3.33) 17 (15.2)
Dysphagia 3 (1.50) 0 (0.00) 0 (0.00) 1 (1.67) 2 (1.79)
Neurological deficits 5 (2.50) 0 (0.00) 0 (0.00) 0 (0.00) 5 (4.46)
Constitutional syndrome 25 (12.5) 3 (14.3) 0 (0.00) 4 (6.67) 18 (16.1)
Other symptoms* 11 (5.50) 0 (0.00) 0 (0.00) 4 (6.67) 7 (6.25)
*, other symptoms: hoarseness, superior vena cava syndrome, abdominal pain and palpation of subcutaneous lesion; **, from symptomat-
ic patients (n=201), one has missing information about stage.
Figure 2 Kaplan-Meier curve of the time between diagnosis and 
all-cause death between patients who were asymptomatic and 
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Figure S2). In the multivariate Cox regression analysis both 
symptomatic presentations confirmed to be independent 
poor prognostic factors (Figure S3).
Discussion
Based on our Lung Cancer FDT registry, we observed that 
asymptomatic patients incidentally diagnosed with lung 
cancer exhibited a significantly better prognosis than those 
who presented symptoms at the time of diagnosis, with 
a 3-year OS of 63.6% (versus 30.3%) and a significantly 
superior median OS (P<0.001). After performing an 
adjusted multivariate Cox regression analysis, we confirmed 
that being symptomatic at the moment of diagnosis was 
an independent risk factor for poor prognosis, with a HR 
of 2.63. Additionally, propensity score matching was used 
to reduce selection bias, and results using matched pairs 
confirm our hypothesis.
In our cohort, 24.7% of patients were incidentally 
diagnosed. Previous studies showed differing incidences, 
what could be mainly due to the different lung cancer 
cohorts explored and different adopted definitions of 
incidental diagnosis. Among surgical lung cancer cohorts, 
there are moderate figures, ranging from 18% from Sheel 
et al. (11), to the 53.9% reported by Quadrelli et al. (12). 
In cohorts not limited to surgical patients, the prevalence 
of asymptomatic patients is lower, and we find values of 
9.1% from Kocher et al. (13) and 6.5% from In et al. (10). 
Although performed in a general lung cancer cohort, our 
study shows a high prevalence of incidental diagnosis. This 
could be partially attributed to our definition of incidental 
diagnosis, particularly affecting chronic respiratory patients. 
Being completely asymptomatic is uncommon in these 
patients, therefore we considered them symptomatic only 
when reporting striking changes in their symptomatology. 
If we had considered only totally symptoms-free patients, 
the percentage of incidental diagnosis may have been 
lower and maybe similar to previously reported figures. 
Kocher et al. (13) preferred to use a stringent definition, 
and only considered patients without any potential lung 
cancer symptom. However, in our opinion, our criterion 
of “asymptomatic” sought to better reflect “real-life” daily 
practice with these chronic patients, which can also present 
their usual symptoms and hide asymptomatic incipient 
malignant lesions.
Also consistent with previous works, patients with 
Figure 3 Hazard ratios (HR) and 95% confidence intervals (CI) for all-cause death. Multivariate Cox regression analysis adjusted by age, 
sex, disease stage, symptoms at diagnosis and ECOG scale. ECOG, Eastern Cooperative Oncology Group.
Hazard ratio
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an incidental diagnosis were significantly older (12,13). 
Age related factors, as comorbidities that may require 
chest imaging and elective surgeries with their previous 
preoperative radiographs, may partially explain these 
results. This could be in line with the results observed with 
respect to comorbidities, as asymptomatic patients have 
shown a higher prevalence of COPD and cerebrovascular 
disease, chronic conditions that can lead to more routine 
imaging.
Furthermore, we observed significant differences in the 
initial stage at diagnosis. Incidentally diagnosed patients 
presented more frequently with localized stage disease, 
while symptomatics presented more frequently with 
advanced disease. This is in line with differences found in 
the initial treatment: asymptomatic patients more frequently 
underwent surgical treatment. Previous works share similar 
results in staging and initial treatment strategies (10-13).
We also drew the conclusion that patients incidentally 
diagnosed with lung cancer have a better prognosis and OS, 
in accordance with previous studies. Kocher et al. reported a 
3-year OS of 62.6% in asymptomatic patients compared to 
30.3% in symptomatics. Additionally, they obtained an HR 
for a symptomatic diagnosis of 1.35 (95% CI, 1.042–1.684; 
P=0.022) (13). These findings, very similar to our results, 
clearly define a tendency for a better prognosis in these 
patients, so we should focus on detecting the disease prior 
to the development of symptoms.
In the past few years, in both the United States and 
Europe, screening lung cancer trials have been developed. 
The National Lung Screening Trial (NLST), was the first 
fully powered randomized controlled trial (RCT) to provide 
evidence of a mortality advantage in computed tomography 
(CT)-screened high-risk patients (20). Recently, the 
NEderlands Leuvens Longkanker Screenings Onderzoek 
(NELSON) study confirmed the findings of the NLST in 
a European population (21). However, for the moment, 
screening is not a homogeneous reality and screening 
procedures are widely variable in different countries. In 
Spain, and consequently in our hospital, there is currently 
no extended lung cancer screening program, so our work 
should be addressed to generating evidence to support this 
approach for early detection.
Our study has some limitations to be commented. 
Our follow-up time and sample were smaller than those 
of previous studies (8-13). This may have decreased the 
power of our results, and a study with a longer follow-up 
period and a larger sample size may have revealed greater 
differences. Nevertheless, our results showed significant 
differences and yielded similar conclusions to those drawn 
from prior works. Also, despite adjusting the model by 
disease stage and ECOG the determination of survival 
time among patients with incidental diagnoses may be 
subjected to lead-time bias. Finally, despite the fact that 
this model has been adjusted by variables such as stage and 
performance status, it has not been possible to adjust for 
biological parameters translating tumor aggressiveness that 
have been shown to be prognostic factors in patients with 
lung cancer (22-24).
Remarkably, our study was developed in a specific lung 
cancer FDT consultation, which provides high quality 
to clinical practice and data underlying this work. Our 
lung cancer FDT is an optimal care pathway. These are 
structured multidisciplinary care plans for specific clinical 
conditions, which describe the tasks to be pursued, their 
timing, sequence and the professionals involved (14). In 
brief, these pathways chart the optimal journey of patients 
with suspected lung cancer. Among their reported aims, 
one of the most significant ones is the reduction of delays 
experienced by patients from investigations to the initial 
treatment phase. This is the objective pursued by our 
FDT, and therefore the slogan that underlies all of our 
clinical practice. All of our results, diagnostic times, the 
patient statistics, are all reported from a consultation that 
aims to optimaze the medical care. In our opinion this 
is our strength and enhances the quality and delivery of 
our work. In addition, this study has been performed in a 
general lung cancer cohort from a circumscribed area, had 
an ambispective design, and was not restricted according 
to histological subtype or received treatment. These 
facts support the potential generalization and clinical 
implications of our results.
In  conc lu s ion ,  l ung  cancer  pa t i en t s  who  a re 
asymptomatic at the time of diagnosis exhibit significantly 
better prognosis, and the presence of symptoms at diagnosis 
constitutes an independent risk factor for a poor prognosis. 
Our efforts should concentrate on continuing further 
research to improve and determine the key points that are 
lacking in the early detection of lung cancer.
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Supplementary
Table S1 Characteristics of patients of the matched paired analysis for the 1:1 propensity score
Variable [ALL] N=122 Asymptomatic N=61 Symptomatic N=61 p.overall
Age, mean (SD) 70.4 (9.54) 70.3 (9.92) 70.4 (9.21) 0.992
Sex 0.799
Male, n (%) 104 (85.2%) 51 (83.6%) 53 (86.9%)
Female, n (%) 18 (14.8%)  10 (16.4%)  8 (13.1%)
Stage, n (%) 0.891
I 40 (32.8%)  21 (34.4%) 19 (31.1%)
II 14 (11.5%)  8 (13.1%)  6 (9.84%)
III 38 (31.1%)  18 (29.5%) 20 (32.8%)
IV 30 (24.6%)  14 (23.0%) 16 (26.2%)
ECOG, n (%) 1.000
0-1 104 (85.2%) 52 (85.2%) 52 (85.2%)
>1 18 (14.8%)  9 (14.8%) 9 (14.8%)
SD: Standard deviation. ECOG: Eastern Cooperative Oncology Group.
Figure S1 Kaplan-Meier curve of the time between diagnosis and all-cause death between patients who were asymptomatic and symptomatic 
at diagnosis, from propensity score (PS) matching analysis. HR: Hazard Ratio. OS: Overall Survival. Symp: symptomatic patients. Asymp: 
asymptomatic patients. 
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Table S2 Clinical and demographic characteristics of patients categorized on asymptomatic, symptomatic with respiratory symptoms and 























Age 68.0 (10.7) 70.9 (9.92) 65.8 (10.4) 67.7 (10.9) 0.015 0.105 0.454
Sex, male, n (%) 223 (83.5%) 55 (83.3%) 54(79.4%) 114 (85.7%) 0.817 0.817 0.817
Stage, n (%) <0.001 <0.001 0.001
I 46 (17.3%) 25 (37.9%) 7(10.4%) 14 (10.5%)
II 16 (6.02%) 9 (13.6%) 0(0.00%) 7 (5.26%)
III 78 (29.3%) 18 (27.3%) 11 (16.4%) 49 (36.8%)
IV 126 (47.4%) 14 (21.2%) 49(73.1%) 63 (47.4%)
Smoking status,  
yes, n(%)













FEV1/FVC, < 70, n (%) 115 (54.0%) 31 (49.2%) 21(50.0%) 63 (58.3%) 1.000 0.689 0.689
FEV1 %, mean (SD) 74.5 (21.4) 77.4 (22.7) 77.2(19.5) 71.8 (21.3) 0.999 0.237 0.347
DLCO, mean (SD),
ml CO/min/mmHg
67.6 (18.0) 67.2 (19.6) 69.3(16.7) 67.1 (17.5) 0.846 0.999 0.802
Histology, n (%) 0.720 0.720 0.720
Squamous 91 (34.1%) 24 (36.4%) 19(27.9%) 48 (36.1%)
Adenocarcinoma 110 (41.2%) 29 (43.9%) 29(42.6%) 52 (39.1%)
Small cell lung 
cancer
37 (13.9%) 8 (12.1%) 13(19.1%) 16 (12.0%)
Other* 29 (10.9%) 5 (7.58%) 7(10.3%) 17 (12.8%)
Deaths, n (%): 164 (61.4%) 24 (36.4%) 53(77.9%) 87 (65.4%) <0.001 <0.001 0.096
Initial treatment, n (%) <0.001 <0.001 0.961
Surgery 56 (21.2%) 28 (42.4%) 8(11.9%) 20 (15.3%)
Chemotherapy 117 (44.3%) 20 (30.3%) 35(52.2%) 62 (47.3%)
 Chemoradiotherapy 57 (21.6%) 8 (12.1%) 16(23.9%) 33 (25.2%)
Radiotherapy 17 (6.44%) 7 (10.6%) 3(4.48%) 7 (5.34%)
Best supportive care 17 (6.44%) 3 (4.55%) 5(7.46%) 9 (6.87%)
ECOG scale, n (%) 0.929 0.913 0.913
0-1 220 (86.6%) 52 (85.2%) 54(83.1%) 114 (89.1%)
>1 34 (13.4%) 9 (14.8%) 11(16.9%) 14 (10.9%)
SD: Standard deviation; p25th; p75th: 25 and 75 percentiles; FEV1: Forced expiratory volume in 1 second; FVC: Forced vital capacity. DLCO: 
the diffusion capacity of carbon monoxide. ECOG: Eastern Cooperative Oncology Group. Total tobacco exposure is expressed in pack-
years. * Other histologies: large cell neuroendocrine carcinoma, carcinoid tumors (typical and atypical), adenosquamous carcinoma and 
undifferentiated non-small cell lung cancer-not otherwise specified (NOS).
© Journal of Thoracic Disease. All rights reserved. http://dx.doi.org/10.21037/jtd-20-3075
Figure S3 Multivariate Cox regression analysis adjusted by age, sex, disease stage, symptoms at diagnosis and ECOG scale. ECOG: Eastern 
Cooperative Oncology Group.
Figure S2 Kaplan-Meier curve of the time between diagnosis and all-cause death between patients who were asymptomatic, symptomatic 
with respiratory symptoms and symptomatic with non-respiratory symptoms at diagnosis. Resp: symptomatic patients with respiratory 
symptoms. Asymp: asymptomatic patients. Non- Resp/ Symp-Non-Resp: symptomatic patients with non-respiratory symptoms. HR: 
Hazard Ratio. OS: Overall Survival.
